Evidence map›Paper›PMID 32301840›Full record

ArticlePain2020

Activation of sphingosine-1-phosphate receptor subtype 1 in the central nervous system contributes to morphine-induced hyperalgesia and antinociceptive tolerance in rodents.

Timothy M Doyle, Kali Janes, Zhoumou Chen, Peter M Grace, Emanuela Esposito, Salvatore Cuzzocrea, Tally M Largent-Milnes, William L Neumann, Linda R Watkins, Sarah Spiegel and 2 more

Erratum issuedOpen access · greenAbstract read
In one paragraph

Article in Pain, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Dysregulation of sphingolipid metabolism in pain.Frontiers in pharmacology · 2024
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 2 countries.

Timothy M DoyleDepartment of Pharmacology and Physiology, Saint Louis University School of Medicine, St. Louis, MO, United States.
Kali JanesDepartment of Pharmacology and Physiology, Saint Louis University School of Medicine, St. Louis, MO, United States.
Zhoumou ChenDepartment of Pharmacology and Physiology, Saint Louis University School of Medicine, St. Louis, MO, United States.
Peter M GraceDepartment of Symptom Research, University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Emanuela EspositoDepartment of Clinical and Experimental Medicine and Pharmacology, University of Messina, Messina, Italy.
Salvatore CuzzocreaDepartment of Clinical and Experimental Medicine and Pharmacology, University of Messina, Messina, Italy.
Tally M Largent-MilnesDepartment of Pharmacology, University of Arizona College of Medicine, Tucson, AZ, United States.
William L NeumannDepartment of Pharmaceutical Sciences, School of Pharmacy, Southern Illinois University Edwardsville, Edwardsville, IL, United States.
Linda R WatkinsDepartment of Psychology and Neuroscience, University of Colorado, Boulder, CO, United States.
Sarah SpiegelDepartment of Biochemistry and Molecular Biology, School of Medicine, Virginia Commonwealth University, Richmond, VA, United States.
Todd W VanderahDepartment of Pharmacology, University of Arizona College of Medicine, Tucson, AZ, United States.
Daniela SalveminiDepartment of Pharmacology and Physiology, Saint Louis University School of Medicine, St. Louis, MO, United States.
Saint Louis University · USUniversity of Arizona · USUniversity of Messina · ITSouthern Illinois University Edwardsville · USThe University of Texas MD Anderson Cancer Center · USUniversity of Colorado Boulder · USVirginia Commonwealth University · US

Funding

Role of opioid-induced S1P/S1PR1 axis activation in neuroinflammatory reponsesR01DA043543 · NIDA · SAINT LOUIS UNIVERSITY · PI SALVEMINI, DANIELA, VANDERAH, TODD W · 2018 to 2020
$1.7M
Role of ceramide in morphine hyperalgesia and toleranceR21DA023056 · NIDA · SAINT LOUIS UNIVERSITY · PI SALVEMINI, DANIELA · 2008 to 2009
$392k
Primary Afferent Transmission in the Trigeminal Dorsal HornF32DE022499 · NIDCR · OREGON HEALTH & SCIENCE UNIVERSITY · PI MILNES, TALLY MARIE · 2011 to 2014
$127k
NIDA NIH HHS R01 DA043543NIDA NIH HHS R21 DA023056NIDCR NIH HHS F32 DE022499
6 · The paper itself

Abstract

abstractMorphine-induced alterations in sphingolipid metabolism in the spinal cord and increased formation of the bioactive sphingolipid metabolite sphingosine-1-phosphate (S1P) have been implicated in the development of morphine-induced hyperalgesia (OIH; increased pain sensitivity) and antinociceptive tolerance. These adverse effects hamper opioid use for treating chronic pain and contribute to dependence and abuse. S1P produces distinct effects through 5 G-protein-coupled receptors (S1PR1-5) and several intracellular targets. How S1P exerts its effects in response to morphine remains unknown. Here, we report that S1P contributes to the development of morphine-induced hyperalgesia and tolerance through S1P receptor subtype 1 (S1PR1) signaling in uninjured male and female rodents, which can be blocked by targeting S1PR1 with S1PR1 antagonists or RNA silencing. In mouse neuropathic pain models, S1PR1 antagonists blocked the development of tolerance to the antiallodynic effects of morphine without altering morphine pharmacokinetics and prevented prolonged morphine-induced neuropathic pain. Targeting S1PR1 reduced morphine-induced neuroinflammatory events in the dorsal horn of the spinal cord: increased glial marker expression, mitogen-activated protein kinase p38 and nuclear factor κB activation, and increased inflammatory cytokine expression, such as interleukin-1β, a cytokine central in the modulation of opioid-induced neural plasticity. Our results identify S1PR1 as a critical path for S1P signaling in response to sustained morphine and reveal downstream neuroinflammatory pathways impacted by S1PR1 activation. Our data support investigating S1PR1 antagonists as a clinical approach to mitigate opioid-induced adverse effects and repurposing the functional S1PR1 antagonist FTY720, which is FDA-approved for multiple sclerosis, as an opioid adjunct.

Indexed as

HyperalgesiaMorphineAnalgesicsAnimalsFemaleMaleMiceRodentiaSphingosine-1-Phosphate ReceptorsAnalgesicsMorphineSphingosine-1-Phosphate Receptors

Identifiers

PMID32301840
PMCPMC7554181
OpenAlexW3016449004

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.